ICON plc (ICLR) : ICON plc (ICLR) had a healthy money flow of $1.08 million into the stock during the Tuesdays trading session. The value of bullish trades on upticks was $6.82 million, whereas, investors only sold shares worth $5.74 million on downticks. The stock closed the day with an up-down ratio of 1.19.The money flow in the block trades to the tune of $0.32 million shows that the bulls were dominant, the large players used the weakness in the stock to accumulate it for the long-term. $1.25 million worth of transactions were on upticks. A paltry $0.93 million worth of block trade transactions on downticks shows that the investors are reluctant to sell the stock down. The total up-down ratio of the upticks vs the downticks in block trades was 1.35. ICON plc (ICLR) stock slid $0.22 intraday and traded at 72.93, a change of -0.3% over previous days close. However, for the week, the company shares are 0.25% compared to previous weeks close.
The company Insiders own 44% of ICON plc shares according to the proxy statements. Institutional Investors own 96.39% of ICON plc shares.
Shares of ICON Public Limited Company rose by 4.79% in the last five trading days and 8.14% for the last 4 weeks. ICON Public Limited Company is up 0.48% in the last 3-month period. Year-to-Date the stock performance stands at -6%.
ICON plc (NASDAQ:ICLR): On Tuesdays trading session , Opening price of the stock was $73.68 with an intraday high of $73.99. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $72.61. However, the stock managed to close at $73.04, a loss of 0.15% for the day. On the previous day, the stock had closed at $73.15. The total traded volume of the day was 518,096 shares.
ICON public limited company (ICON) is an Ireland-based contract research organization (CRO), providing outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company is engaged in the strategic development, management and analysis of programs that support the various stages of the clinical development process, from compound selection to Phase I-IV clinical studies. ICONs services include clinical trials management, biometric activities, consulting, imaging, contract staffing, informatics and laboratory services. ICON also conducts various laboratory tests on the patients blood, urine and other bodily fluids at appropriate intervals during the trial. The Companys information systems offerings include ICONIK, Firecrest, iDOC, iLearn, ADDPLAN, AptivAdvantage and AptivInsite. ICON, through its subsidiaries, also provides payer-validated market access solutions, and clinical trial consulting and regulatory support.